Population Prevalence and Incident HPA ‐1a Alloimmunisation in Pregnancy: A Prospective, Multi‐Ethnic, Natural History Study
- 13 September 2026
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Abstract
Objective: Foetal‐neonatal alloimmune thrombocytopaenia (FNAIT) is a rare disease, most commonly caused by maternal alloantibodies to human platelet antigen (HPA)‐1a that can result in severe bleeding. The present study was designed to determine the frequency of higher risk for HPA‐1a alloimmunisation and development of FNAIT among a racially and ethnically diverse cohort of pregnant women. Design: Longitudinal, prospective, non‐interventional, natural history study. Setting: Conducted across 28 sites in North America and Europe. Population: Pregnant women (≥ 18 years) with no history of FNAIT. Methods: Blood samples were collected at 10–14 weeks' gestation and a sequential screening algorithm applied: maternal HPA‐1a/1b genotyping, human leukocyte antigen [HLA]‐DRB3*01:01 allele status, anti‐HPA‐1a antibody status and foetal HPA‐1 genotype. Main Outcome Measures: Number of women at higher risk for HPA‐1a alloimmunisation (i.e., those who are HPA‐1b/b, HLA‐DRB3*01:01 positive, anti‐HPA‐1a antibody negative and carrying an HPA‐1a‐positive foetus) that alloimmunise. Results: Of the 14 114 participants screened, 1.7% were HPA‐1b/1b genotype, which varied according to race and geography. Of 24 women at higher risk for FNAIT, five were lost to follow‐up with no post‐partum test for alloimmunisation. At Week 10 post‐partum, 2/19 higher risk participants (11%; 95% confidence interval [CI]: 1.3%, 33.1%) demonstrated anti‐HPA‐1a antibodies, while 17 remained negative. Pre‐existing anti‐HPA‐1a antibodies were identified in 18 other HPA‐1bb, DRB3*01:01 positive women at screening. Conclusions: This prospective study confirms the rarity of a population at higher risk for HPA‐1a alloimmunisation and FNAIT, describes the risk among Black and Asian women, and establishes a rigorous methodology to assess for risk of HPA‐1a immunisation.Keywords
This publication has 18 references indexed in Scilit:
- Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort studyThe Lancet Haematology, 2023
- Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatmentBlood Reviews, 2022
- New developments in fetal and neonatal alloimmune thrombocytopeniaAmerican Journal of Obstetrics and Gynecology, 2021
- Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT)BJOG: An International Journal of Obstetrics & Gynaecology, 2019
- Fetal and neonatal alloimmune thrombocytopeniaSeminars in Fetal and Neonatal Medicine, 2016
- Fetal/Neonatal Allo-Immune Thrombocytopenia (FNAIT): Past, Present, and FutureObstetrical & Gynecological Survey, 2008
- Real-time PCR genotyping of human platelet alloantigens HPA-1, HPA-2, HPA-3 and HPA-5 is superior to the standard PCR-SSP methodTransfusion Medicine, 2004
- Gene frequencies of the five major human platelet antigens in African American, white, and Korean populationsTransfusion, 1995
- Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot studyBritish Journal of Haematology, 1995
- 348 CASES OF SUSPECTED NEONATAL ALLOIMMUNE THROMBOCYTOPENIAThe Lancet, 1989